Beta Blocker Intolerance: Genetic Testing to Explain Side Effects

Beta Receptor Polymorphism and Intolerance to Beta Blockade in Patients with Heart Failure or Ischaemic Heart Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12616000491460

Enrollment

200

Registered

2016-04-14

Start date

2016-09-01

Completion date

2017-04-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A beta blocker is a type of medication that is commonly given to cardiac patients. This medication has been shown to reduce the risk of death in patients who have suffered a heart attack, or in those who experience heart failure. Beta blockers are associated with some side effects that may affect individual patients differently and may prevent their use in certain patients. In this project, the researchers will study the genetic differences between patients who can take this medicine and those who are unable to tolerate the side effects. At the end of the study, we hope to have improved our understanding of how genetic differences may affect the use of this important medication.

Interventions

Patients with heart failure or ischaemic heart disease plus a history of intolerance to beta blockers (e.g. metoprolol) will have their blood samples taken. DNA analysis will be conducted to determine if beta receptor polymorphisms are associated with intolerance to this class of medicine.

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

Systolic Heart Failure NYHA II-IV or Ischaemic Heart Disease At least one documented dose of beta blocker Documented intolerance to beta blocker (cases) - wheeze / bradycardia Documented tolerance to beta blockers (controls)

Exclusion criteria

Diastolic Heart Failure Hypertrophic Cardiomyopathy Renal / Hepatic Failure

Outcome results